Phase II Study of Anti–Gastrin-17 Antibodies, Raised to G17DT, in Advanced Pancreatic Cancer

2002110 citationsJournal Article

Authors

Bernard Brett · The Royal Free Hospital

S C L Smith · The Royal Free Hospital

C. V. Bouvier · The Royal Free Hospital

D Michaeli · The Royal Free Hospital

Daniel Hochhauser · The Royal Free Hospital

BR Davidson · The Royal Free Hospital

Tom Kurzawinski ·

Abstract

Patients with advanced pancreatic cancer are able to mount an adequate antibody response to G17DT. The 250- micro g dose is superior to the 100- micro g dose, and it appears to be generally well tolerated. Antibody responders demonstrate significantly greater survival than antibody nonresponders. Phase III studies are currently underway in order to determine efficacy.

Topics & Keywords

Pancreatic and Hepatic Oncology Research Neuroendocrine Tumor Research Advances Peptidase Inhibition and Analysis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 20, Issue 20, pp. 4225-4231

DOI: 10.1200/jco.2002.11.151

Field-Weighted Citation Impact: 4.15